张海军,方海

• 1:北京大学公共卫生学院
• 2:北京大学医学部-中国疾病预防控制中心疫苗经济学联合研究中心
• 3:北京大学中国卫生发展研究中心

摘要(Abstract)：

目的分析b型流感嗜血杆菌(Hib)疫苗纳入国家免疫规划(NIP)的成本效益。方法从文献和相关部门收集模型参数,从全社会角度构建决策树-Markov模型,计算Hib疫苗未纳入和纳入NIP中国2017年出生儿童的Hib疫苗接种成本、Hib相关疾病经济负担,分析Hib疫苗纳入NIP的效益成本比(BCR),并进行模型的单因素敏感性分析。结果 Hib疫苗未纳入和纳入NIP中国2017年出生儿童的Hib疫苗接种成本分别为281 925万元和989 836万元,Hib相关疾病的经济负担分别为93 993万元、10 559万元;Hib疫苗纳入NIP产生的净效益为-445 788万元,BCR为0.59。当纳入NIP的每剂次Hib疫苗价格从当前的平均价格79元降至<53元时,BCR>1。结论 Hib疫苗按当前平均价格纳入NIP不节约社会成本;Hib疫苗纳入NIP需降低疫苗成本。

关键词(KeyWords)： b型流感嗜血杆菌疫苗;国家免疫规划;成本效益;决策树-Markov模型

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张海军,方海

参考文献(References)：

• [1]HE C,LIU L,CHU Y,et al.National and subnational allcause and cause-specific child mortality in China,1996-2015:a systematic analysis with implications for the sustainable development goals[J].The Lancet Global Health,2017,5(2):186-197.
• [2]NANDURI SA,SUTHERLAND AR,GORDON LK,et al.Haemophilus influenzae type b vaccines[M].Philadelphia:Elsevier,2018:301-318.
• [3]WAHL B,O'BRIEN KL,GREENBAUM A,et al.Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines:global,regional,and national estimates for 2000-15[J].The Lancet Global Health,2018,6(7):744-757.
• [4]WHO.Haemophilus influenzae type b(Hib)vaccination WHO position paper:July 2013-recommendations[J].Vaccine,2013,31(52):6168-6169.
• [5]LEVINE OS,KNOLL MD,JONES A,et al.Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines:evidence,policies,and introductions[J].Current Opinion in Infectious Diseases,2010,23(3):236-241.
• [6]International Vaccines Access Center.VIEW-hub[EB/OL].(2020-03-15)[2020-10-08].http://www.view-hub.org.
• [7]PELTOLA H.Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century:global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates[J].Clinical Microbiology Reviews,2000,13(2):302-317.
• [8]WATT JP,WOLFSON LJ,O'BRIEN KL,et al.Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years:global estimates[J].The Lancet,2009,374(9693):903-911.
• [9]U.S.Center for Disease Control and Prevention.Haemophilus influenzae type b signs and symptoms[EB/OL].(2019-04-15)[2020-010-08].https://www.cdc.gov/hidisease/about/sy mptoms.html.
• [10]YU W,LU M,WANG H,et al.Routine immunization services costs and financing in China,2015[J].Vaccine,2018,36(21):3041-3047.
• [11]WHO.Revising global indicative wastage rates:a WHO initiative for better planning and forecasting of vaccine supply needs[R].Geneva,2019.
• [12]国家卫生和计划生育委员会.2018年中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版,2018.
• [13]国家统计局.2018年中国人口与就业统计年鉴[M].北京:中国统计出版社,2018.
• [14]EDMOND K,CLARK A,KORCZAK VS,et al.Global and regional risk of disabling sequelae from bacterial meningitis:a systematic review and meta-analysis[J].The Lancet Infectious Diseases,2010,10(5):317-328.
• [15]宁桂军,王旭霞,刘世文,等.2015-2016年甘肃省白银市5岁以下儿童社区获得性肺炎疾病负担回顾性调查[J].中国疫苗和免疫,2017,23(1):18-21+12.
• [16]刘文婷.部分地区三种主要细菌性脑膜炎病例经济负担调查[D].北京:中国疾病预防控制中心,2016.
• [17]国家统计局.中国2010年人口普查资料[M].北京:中国统计出版社,2010.
• [18]GRIFFITHS KU,CLARK A,GESSNER B,et al.Dosespecific efficacy of Haemophilus influenzae type b conjugate vaccines:a systematic review and metaanalysis of controlled clinical trials[J].Epidemiology and Infection,2012,140(8):1343-1355.
• [19]曹雷,王华庆,郑景山,等.中国扩大国家免疫规划疫苗接种率调查分析[J].中国疫苗和免疫,2012,18(5):419-424+478.
• [20]WHO.WHO guide for standardization of economic evaluations of immunization programmes[M].2nd edition.Geneva:World Health Organization,2019.
• [21]张海军,方海.b型流感嗜血杆菌疫苗纳入免疫规划的卫生经济学研究系统评价[J].中国疫苗和免疫,2020,26(4):455-459+473.
• [22]BARNIGHAUSEN T,BLOOM DE,CANNING D,et al.Rethinking the benefits and costs of childhood vaccination:the example of the Haemophilus influenzae type b vaccine[J].Vaccine,2011,29(13):2371-2380.
• [23]宁桂军.白银市儿童肺炎疾病负担与免疫规划经济学评价研究[D].北京:中国疾病预防控制中心,2017.